Press Releases

May 04, 2021, 07:30 ET CRANBURY, N.J., May 4, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United States Patent and Trademark Office (USPTO) issued Notices of Final Determination and Requirement for […]

Positive clinical data from its Phase 2 study of PL9643 in dry eye disease Pre-clinical data with melanocortins for retinal inflammation Apr 20, 2021, 07:30 ET CRANBURY, N.J., April 20, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin

Mar 05, 2021, 07:30 ET CRANBURY, N.J., March 5, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright

— Positive Results from Phase 2 Clinical Study of PL9643 in Patients with Dry Eye Disease — Continue to Rebuild Commercial Infrastructure and Brand Awareness for Vyleesi® — Approximately $72.2 Million in Cash and Cash Equivalents at December 31, 2020 — Teleconference and Webcast to be held on February 17, 2021 at 11:00 AM ET

Feb 12, 2021, 07:30 ET CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

Application Could Provide U.S. and International Patent Coverage for PL9643, Palatin’s Lead Compound for Dry Eye Disease Phase 2/3 Clinical Trial Currently Planned for Mid-2021 Feb 10, 2021, 07:30 ET CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the

Statistically Significant Improvement in Moderate-to-Severe Patients for Multiple Sign and Symptom Measures Phase 2/3 Clinical Trial Currently Planned for Mid-2021 Conference Call and Webcast Today at 8:00 a.m. ET Dec 15, 2020, 07:00 ET CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based

– Regained North American Rights to Vyleesi® for HSDD with Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Clinical Results of PL9643 for the Treatment of Dry Eye Disease on Track for December 2020 – $86.6 Million in Cash and Cash Equivalents as of September 30, 2020

Nov 12, 2020, 07:30 ET CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

– $82.9 Million in Cash and Cash Equivalents at June 30, 2020 – Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi® in July 2020 Resulted in Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Study Data of PL9643 for the Treatment of Dry Eye Disease